Potential of transposon-mediated cellular reprogramming towards cell-based therapies  

作　　者：Dharmendra Kumar Taruna Anand Thirumala R Talluri Wilfried A Kues 

机构地区：[1]Animal Physiology and Reproduction Division,ICAR-Central Institute for Research on Buffaloes,Hisar 125001,India [2]NCVTC,ICAR-National Research Centre on Equines,Hisar 125001,India [3]Equine Production Campus,ICAR-National Research Centre on Equines,Bikaner 334001,India [4]Friedrich-Loeffler-Institut,Institute of Farm Animal Genetics,Department of Biotechnology,Mariensee 31535,Germany

出　　处：《World Journal of Stem Cells》2020年第7期527-544,共18页世界干细胞杂志（英文版）（电子版）

摘　　要：Induced pluripotent stem(iPS)cells present a seminal discovery in cell biology and promise to support innovative treatments of so far incurable diseases.To translate iPS technology into clinical trials,the safety and stability of these reprogrammed cells needs to be shown.In recent years,different non-viral transposon systems have been developed for the induction of cellular pluripotency,and for the directed differentiation into desired cell types.In this review,we summarize the current state of the art of different transposon systems in iPS-based cell therapies.

关 键 词：TRANSPOSONS Induced pluripotent stem cells Clinical applications Cellular reprogramming Cell-based therapy Genetic correction 

分 类 号：R318[医药卫生—生物医学工程]